-
Progress on EXO-NET® commercialisation with Academia and Industry
-
INOVIQ presented on EXO-NET and exosomes to the Preterm Birth International Collaborative #PREBIC Australasian Workshop, held on 21 March 2023 in Brisbane
-
SubB2M CA15-3 breast cancer test outperforms a leading commercially available CA15-3 tumour marker test
-
SubB2M breast cancer and ovarian cancer tests remain on-track to be launch-ready by end of H1 FY24
-
Chief Scientific Officer, Professor Greg Rice, awarded the prestigious Joan Hunt IFPA Senior Award in Placentology for 2023
-
Cash balance of $8.83m as at 31 March 2023, with final payment for settlement of legal proceedings now complete
Melbourne, Australia, 28 April 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) today released its Appendix 4C and Quarterly Business Update for the quarter ended 31 March 2023 (Q3 FY23).
For more information, download the attached PDF.
Download this document
